2023-07-28T12:32:35-05:00 2022-12-31 111986323 MARCUM LLP 1 RESEARCH COURT SUITE 400 ROCKVILLE MD 20850 990 2022-01-01 522275294 SARCOMA FOUNDATION OF AMERICA INC SARC 3012538687 9899 MAIN STREET SUITE 204 204 DAMASCUS MD 20872 BRANDI CLEARY-FELSER CEO 3012538687 2023-07-16 1 BRANDI CLEARY-FELSER 999009999 0 KIMBERLY HODOR MAXWELL CPA P00097044 3016913600 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z MARK THORNTON MD PH 9899 MAIN STREET SUITE 204 204 DAMASCUS MD 20872 4932889 0 X WWW.CURESARCOMA.ORG X 2000 MD WE ADVOCATE FOR SARCOMA PATIENTS BY FUNDING RESEARCH, INCREASING AWARENESS, & PROVIDING PATIENT EDUCATION. 9 9 13 160 0 0 3432529 3559687 0 0 418593 182932 122240 -68596 3973362 3674023 1126322 1074949 0 0 838782 1126705 19998 21973 179056 411459 466510 2396561 2690137 1576801 983886 9642356 9805602 319688 539176 9322668 9266426 X THE MISSION OF THE SARCOMA FOUNDATION OF AMERICA IS TO ADVOCATE FOR SARCOMA PATIENTS BY FUNDING RESEARCH AND BY INCREASING AWARENESS ABOUT THE DISEASE. THE ORGANIZATION RAISES MONEY TO PRIVATELY FUND GRANTS FOR SARCOMA RESEARCHERS AND CONDUCTS EDUCATION AND ADVOCACY EFFORTS ON BEHALF OF SARCOMA PATIENTS. 0 0 2125600 1074949 641 THE SARCOMA FOUNDATION OF AMERICA (SFA) COORDINATES A NATIONAL RESEARCH GRANT PROGRAM THAT FUNDS TRANSLATIONAL SCIENCE SARCOMA RESEARCH. IN ACCORDANCE WITH THE MISSION OF THE SFA, RESEARCH INVOLVING THE DEVELOPMENT OF NOVEL AGENTS AGAINST SARCOMA, OR RESEARCH THAT COULD POTENTIALLY LEAD TO THE DEVELOPMENT OF NOVEL AGENTS AGAINST SARCOMA, IS SUPPORTED THROUGH THIS FUNDING. THE SFA ENGAGES IN PATIENT EDUCATION PROGRAMS ON THE LATEST DEVELOPMENTS IN SARCOMA RESEARCH AND TREATMENTS. THESE EDUCATION INITIATIVES ARE DESIGNED TO FURTHER STRENGTHEN AND DEEPEN PATIENTS' ABILITY TO PARTICIPATE IN THEIR CARE AND RESEARCH PROJECTS. SFA ALSO CONDUCTS ADVOCACY ACTIVITIES ON BEHALF OF THE SARCOMA COMMUNITY TO ENSURE ADEQUATE FEDERAL CANCER RESEARCH FUNDING LEVELS AND POLICIES THAT POSITIVELY IMPACT SARCOMA PATIENTS. 2125600 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 21 0 1 13 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 9 9 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA CT FL GA IL KY MA MD MI MN NC NJ NY OR PA SC VA TN UT WV WI MS RI AL AR HI KS NH NM X X THE ORGANIZATION 3012538687 9899 MAIN STREET SUITE 204 204 DAMASCUS MD 20872 MARK THORNTON MD PHD PRESIDENT 3.00 X X 0 0 0 JOHN SJ BROOKS MD VICE PRESIDENT 1.00 X X 0 0 0 PATRICIA THORNTON TREASURER 3.00 X X 0 0 0 CHRISTOPHER CONNERY DIRECTOR 1.00 X 0 0 0 MICHAEL LEWIS DIRECTOR 1.00 X 0 0 0 JUSTIN GREEN DIRECTOR 1.00 X 0 0 0 BRUCE MARCH DIRECTOR 1.00 X 0 0 0 THOMAS PEROULAS DIRECTOR 1.00 X 0 0 0 JENNIFER GOODWIN DIRECTOR/SECRETARY 1.00 X X 0 0 0 BRANDI CLEARY-FELSER CEO 40.00 X 202503 0 21717 202503 0 21717 1 0 1 0 0 10402 1242152 2307133 36146 3559687 125588 125588 900016 842672 57344 57344 57344 346957 1242152 416194 -69237 -69237 MISCELLANEOUS REVENUE 900099 641 641 641 3674023 641 0 113695 724949 724949 350000 350000 224220 179376 22422 22422 732997 469856 178532 84609 29214 18781 7066 3367 73645 47987 17233 8425 66629 45003 14158 7468 28836 28836 21973 21973 40314 40314 58677 34460 24217 30420 20546 6464 3410 47269 31028 10068 6173 42349 42349 84851 57310 18030 9511 21241 21241 12350 12350 17475 11803 3713 1959 9378 6334 1993 1051 TELEPHONE AND INTERNET 21322 18372 1931 1019 REPAIRS AND MAINTENANCE 19459 13143 4135 2181 REGISTRATION FEES 13835 9344 2940 1551 PRINTING AND REPRODUCTI 13813 6922 3118 3773 4921 4446 311 164 2690137 2125600 385481 179056 496339 1062065 2290692 1409675 191217 164128 54871 44871 80212 45521 180552 119283 68075 61269 6448062 6782147 12888 235926 9642356 9805602 139855 163354 123792 106449 56041 269373 319688 539176 X 7201195 7369811 2121473 1896615 9322668 9266426 9642356 9805602 983886 -1040128 0 X X 0 1 X 1 0 X 2645653 3201729 2294899 3432529 3559687 15134497 552545 573280 266795 270951 346957 2010528 3198198 3775009 2561694 3703480 3906644 17145025 0 0 0 17145025 96149 119761 112890 97262 125558 551620 96149 119761 112890 97262 125558 551620 78258 13772 398 664 641 93733 3372605 3908542 2674982 3801406 4032843 17790378 0.96370 0.95830 0.03100 0.02590 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 861 861 2689276 2690137 284507 71127 0 0 308577 247975 269828 284507 1110887 1666331 11303 1190 511 861 13865 77144 61994 67457 71127 277722 416583 631 110 741 892197 140000 -126977 905220 705148 90000 97049 892197 507777 135245 62126 705148 290231 162987 54559 507777 273207 25000 -7976 290231 0.68550 0.31450 0 0 78190 36235 41955 63362 44048 19314 39000 39000 0 61269 OPERATING LEASE LIABILITY 269373 269373 X 2802321 -1040128 53996 -986132 3788453 40314 -154744 -114430 3674023 2858563 53996 154744 208740 2649823 40314 40314 2690137 PART V, LINE 4: TO SUPPORT INNOVATIVE RESEARCH PROPOSALS WHOSE RESULTS COULD LEAD TO THE DEVELOPMENT OF NEW AND BETTER DRUGS OR BIOLOGIC AGENTS FOR THE TREATMENT OF SARCOMA. PART X, LINE 2: INCOME TAXES NO PROVISION HAS BEEN MADE FOR INCOME TAXES, SINCE THE ORGANIZATION HAS BEEN DETERMINED TO BE EXEMPT FROM INCOME TAX PURSUANT TO INTERNAL REVENUE CODE SECTION 501(C)(3). THERE WAS NO NET UNRELATED BUSINESS TAXABLE INCOME DURING THE YEAR. THE ORGANIZATION ADOPTED THE FINANCIAL ACCOUNTING STANDARDS BOARD FASB ASC 740-10, INCOME TAXES, WHICH REQUIRES AN ASSESSMENT OF UNCERTAINTY IN INCOME TAXES AND CERTAIN FINANCIAL STATEMENT DISCLOSURES RELATING TO UNRECOGNIZED TAX BENEFITS. FOR THE YEAR ENDED DECEMBER 31, 2022, THE ORGANIZATION HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS EXIST REQUIRING EITHER RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. NO RETURNS ARE CURRENTLY UNDER EXAMINATION. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSES INCLUDED ON 990 LINE 8B WHICH WERE NOT A DIRECT BENEFI TO THE DONOR, INCLUDED AS FUNDRAISING EXPENSE FOR AUDIT PURPOSES. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING EXPENSES INCLUDED ON 990 LINE 8B WHICH WERE NOT A DIRECT BENEFI TO THE DONOR, INCLUDED AS FUNDRAISING EXPENSE FOR AUDIT PURPOSES. PART XI LINE 4B, AND PART XII LINE 2D FUNDRAISING EXPENSES INCLUDED ON 990 LINE 8B WHICH WERE NOT A DIRECT BENEFIT TO THE DONOR WERE INCLUDED AS FUNDRAISING EXPENSE FOR AUDIT PURPOSES. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES CANCER RESEARCH 300000 NORTH AMERICA 0 0 PROGRAM SERVICES CANCER RESEARCH 50000 0 0 0 0 0 0 350000 0 350000 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CANCER RESEARCH 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CANCER RESEARCH 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CANCER RESEARCH 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 50000 WIRE 0 NORTH AMERICA CANCER RESEARCH 50000 WIRE 0 7 0 0 0 0 0 0 PART I, LINE 2: GRANTEES ARE REQUIRED TO PROVIDE FINAL SCIENTIFIC REPORT AND FINAL FINANCIAL REPORT AFTER THE CONCLUSION OF THE ONE-YEAR GRANT PERIOD. PART III ACCOUNTING METHOD: X X X 1 POWERED BY PROFESSIONALS INC 1460 BROADWAY 9TH FLOOR NEW YORK NY 10036 CONSULTING, MANAGEMENT, AND FUNDRAISING SERVICES FOR GALA 0 230000 21973 230000 230000 21973 230000 CA CT FL GA IL MA MD MI MN NC NJ NY OR VA WI MS RI TN UT WV AL PA SC KY CO OH WA MO AK AR DC HI KS ME NV NH NM OK GALA 537041 510966 26075 20000 111982 CHICAGO (RTCS 2022) 141413 109742 31671 2000 19413 18 910655 621444 289211 30643 502 11879 239188 1589109 1242152 346957 32643 502 31879 370583 435607 -88650 SCHEDULE G, PART I, LINE 2B, COLUMN (V) CURRENT CONTRACT- $3,995 PER MONTH. CURRENT YEAR PAYMENTS WERE $43,945 PORTION RELATED TO EVENT PROGRAM: $17,578, MANAGEMENT: $4,394, PORTION RELATED TO FRP: $21,973. 1 UNIVERSITY OF MARYLAND BALTIMORE 526002033 STATE 10000 0 CANCER RESEARCH ST JUDE CHILDREN'S RESEARCH HOSPITAL INC 620646012 501C(3) 50000 0 CANCER RESEARCH UNIVERSITY OF TX MD ANDERSON CANCER CENTER 746001118 501C(3) 100000 0 CANCER RESEARCH INDIANA UNIVERSITY 356001673 STATE 50000 0 CANCER RESEARCH REGENTS OF THE UNIVERSITY OF MINNESOTA 416007513 STATE 50000 0 CANCER RESEARCH DANA-FARBER CANCER INSTITUTE INC 042263040 501C(3) 50000 0 CANCER RESEARCH REGENTS OF THE UNIVERSITY OF COLORADO 846000555 STATE 50000 0 CANCER RESEARCH THE OHIO STATE UNIVERSITY 316025986 STATE 50000 0 CANCER RESEARCH CITY OF HOPE 953435919 501C(3) 50000 0 CANCER RESEARCH WILLIAM MARSH RICE UNIVERSITY 741109620 501C(3) 50000 0 CANCER RESEARCH UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER 626001636 STATE 50000 0 CANCER RESEARCH MAYO CLINIC 416011702 501C(3) 50000 0 CANCER RESEARCH CLEVELAND CLINICPHILANTROPHY INSTITUTE 340714585 501C(3) 53180 0 CANCER RESEARCH SITEMAN CANCER CENTER 430653611 501C(3) 46243 0 CANCER RESEARCH PART I, LINE 2: APPLICANTS FOR SFA GRANTS MUST SUBMIT AN APPLICATION OUTLINING THEIR PROPOSED RESEARCH PROJECT ALONG WITH A DETAILED BUDGET THAT DEMONSTRATES HOW THE AWARD MONEY IS TO BE USED. APPLICANTS ARE MADE AWARE THAT A REQUIREMENT OF THE ACCEPTANCE OF GRANT MONEY IS THAT A FINAL REPORT WILL BE SUBMITTED TO SFA AT THE END OF THE ONE-YEAR GRANT PERIOD. THE FINAL REPORT AND BUDGET IS DUE TO SFA BY JULY 31ST OF THE YEAR AFTER THE AWARD IS MADE. FINAL REPORTS ARE TO CONTAIN INFORMATION ON HOW THE RESEARCH PROGRESSES AND IT MUST BE SIGNED BY BOTH THE PRIMARY INVESTIGATOR AS WELL AS THEIR DEPARTMENT CHAIR. X X X X 0 0 0 0 0 0 0 0 0 BRANDI CLEARY-FELSER CEO 187503 0 15000 0 0 0 7632 0 14085 0 224220 0 0 0 PART I, LINE 3 THE BOD HAS AN APPOINTED COMPENSATION COMMITTEE THAT ON AN ANNUAL BASIS REVIEWS AND RECOMMENDS TO THE BOARD THE SALARY OF THE CEO USING CURRENT ECONOMIC DATA. X 11 2000 FMV X 168 X 2 11184 FMV X VACATION PACAKAGES 31 13720 FMV X GIFT BASKETS 40 4979 X EVENT AND SPORTS PASSES 11 1536 X GIFT CARDS 11 1186 X HELMET 1 600 X COLLAGE 2 525 X LABEL BOTTLES 2 160 X JEWELRY 1 88 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 MARK THORNTON, PRESIDENT, AND PATRICIA THORNTON, TREASURER, ARE HUSBAND AND WIFE. FORM 990, PART VI, SECTION B, LINE 11B THE DIRECTOR OF FINANCE AND ADMINISTRATION, TREASURER AND CEO REVIEW THE 990 BASED ON THE FINANCIAL RECORDS, POLICIES AND PROGRAMS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 12C AT LEAST ONCE A YEAR, OFFICERS ACTING ON BEHALF OF THE SARCOMA FOUNDATION OF AMERICA, INC., SHALL EXECUTE AND SUBMIT A STATEMENT TO THE PRESIDENT DISCLOSING ALL MATERIAL FACTS CONCERNING ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST OR CONFIRMING THAT THERE ARE NO SUCH CONFLICTS TO BE DISCLOSED. FORM 990, PART VI, SECTION B, LINE 15A THE BOARD OF DIRECTORS HAS AN APPOINTED COMPENSATION COMMITTEE THAT ON AN ANNUAL BASIS, REVIEWS AND RECOMMENDS TO THE BOARD THE SALARY OF THE CEO USING CURRENT ECONOMIC DATA. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS ARE AVAILABLE ON THE WEBSITE AS WELL AS UPON REQUEST. FORM 990, PART XII, LINE 26 THE ORGANIZATION HAS NOT CHANGED EITHER ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR.